Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nexalin Technology, Inc.

< Previous 1 2 Next >
News headline image
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
News headline image
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.